We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

30 hedge funds and large institutions have $364K invested in Navidea Biopharmaceuticals Inc. in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

7% more funds holding

Funds holding: 28 → 30 (+2)

11% less capital invested

Capital invested by funds: $410K → $364K (-$45.4K)

73% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 11

83% less call options, than puts

Call options by funds: $1K | Put options by funds: $6K

Holders
30
Holders Change
+2
Holders Change %
+7.14%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
11
Closed
2
Calls
$1K
Puts
$6K
Net Calls
-$5K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$50.5K
2
Millennium Management
Millennium Management
New York
+$37.6K
3
ACM
Allred Capital Management
Texas
+$15.9K
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$292
5
TRCT
Tower Research Capital (TRC)
New York
+$3

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$111K
2
WAM
Warberg Asset Management
Illinois
-$38.9K
3
Citadel Advisors
Citadel Advisors
Florida
-$8.19K
4
VF
Virtu Financial
New York
-$5.07K
5
PFO
Pathstone Family Office
New Jersey
-$2.93K
Name Holding Trade Value Shares
Change 		Change in
Stake
KFS
26
Kelly Financial Services
Massachusetts
$13 – – –
BCMLT
27
Beacon Capital Management LLC (Tennessee)
Tennessee
$3 – – –
CTB
28
Country Trust Bank
Illinois
$2 +$2 +7 New
HF
29
HRT Financial
New York
– -$2K -12,614 Closed
PP
30
PDS Planning
Ohio
– -$2.22K -10,565 Closed
1
2

NAVB Hedge Fund Activity: Q1 2023 in Review

30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2023, worth a combined $364K — down 11% from $410K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NAVB positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 11 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $50.5K. The largest seller was Vanguard Group, cutting an estimated $111K.

  • 30 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2023, up from 28 in Q4 2022.
  • Funds reported $364K of Navidea Biopharmaceuticals Inc. stock for Q1 2023, down 11% quarter-over-quarter.
  • 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2023 and 2 closed out, a net change of +2 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2023 was Renaissance Technologies, an estimated $50.5K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2023 was Vanguard Group, an estimated $111K sold.

Based on aggregated 13F filings for Q1 2023.